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1. Introduction  
Pharmacogenetics is focused on finding associations between drug response and the genetic 
background of a patient.38 Resequencing of the human genome revealed that nucleotide 
variation between individuals exists in 0.1% of the genome, which corresponds to 3 million 
differences. These variations occur in more than 1% of a population and are designated as 
single nucleotide polymorphisms (SNP), normally not causing any disease. Functional 
variants caused by SNPs in drug related genes (such as metabolism enzymes, transporters 
and receptors) have become of interest more and more in recent years.21,22,40,73 Variations 
that occur less frequent than 1% are designated as mutations and could be disease causing. 
Pharmacogenetic research has been expanded dramatically, with 1334 publications in the 
past century starting from 1961, while 7654 papers have been published since the year 2000 
(pubmed accession date: November 18, 2010). The ultimate goal of pharmacogenetic 
research is the establishment of personalized medicine, aiming in prescribing the best choice 
of drug with the optimal concentration.67 Even the route of administration could be 
considered. At present, pharmacogenetics is not applied widely in clinical practice as a 
diagnostic tool, but is mainly restricted to research, which is, finding associations between 
drug response and genetic background within a group of patients. Much research is being 
performed in order to achieve a more beneficial cancer therapy, although pharmacogenetic 
research is also active in other fields like rheumatoid arthritis,7,42,52 transplantation50,84 and 
diabetes.19,51  
The application of whole genome techniques for predicting patients’ sensitivity or resistance 
to a drug is the definition of pharmacogenomics.27,68  
At present, most pharmacogenetic research is focused on enzymes that control the 
metabolism and uptake of many clinically used drugs. Most of these drugs are metabolized 
by Cytochrome P450 of which variant alleles are common that affects drug 
effectiveness.15,24,33 Roche diagnostics has developed an array to screen for the most 
important SNPs in Cytochrome P450 isoenzyme 2D6.72 This array is the first one that is 
approved by FDA for diagnostic testing. Other interesting genes with relatively high 
frequency of variant alleles are transporters such as MDR1.5,41,70 Affymetrix had developed 
an array (DMET) to screen for 1936 SNPs in genes that are involved in drug metabolism, 
uptake and detoxification.16  
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Although screening for SNPs in DNA mismatch repair enzymes is a standard method  
for diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC),45,61 pharmacogenetics 
of DNA repair enzymes is only applied in research settings and is discussed later in  
this chapter. 
2. Genetic characteristics of tumor cells 
When a normal cell loses the ability to regulate its own cell division but instead 
continuously divides, then this cell has become a tumor cell (reviewed by Hanahan and 
Weinberg25). Benign tumors result from minor imbalances in tissue whereby too many 
genetically stable cells are produced. These cells grow expansively and since they are often 
encapsulated, they can be removed by surgery. Since blood cells travel throughout the body, 
clonal expansion of these cells never result in benign tumors, but always in malignant 
tumors. Malignant tumors are genetically instable, metastasize easily and are causing 
cancer. These type of tumors can only be removed by surgery if they are caught in early 
development, but many solid tumors smaller than 1 cm have already been metastasized. 
Due to their genetic instability, tumor cells have different genetic characteristics and 
consequently a heterogeneous phenotype. In such a heterogeneous population, the cells that 
are best adapted to their environment survive better than the less malignant ones. Genetic 
alterations consist of “loss of heterozygosity”, translocations, mutations and disturbance in 
methylation.  
3. Platinum drugs for cancer treatment 
The treatment of cancer depends fully on the type of tumor and often several approaches 
are made to kill the tumor. Antibodies are frequently used to block receptors that are over 
expressed in the tumor, or to scavenge growth stimulating factors. For example the 
epidermal growth factor receptor (EGFR) is essential for normal cellular function, however, 
increased levels of EGFR mRNA are associated with metastasis and aggressive tumor 
growth.39 EGFR is over expressed in tumor cells and many therapies are focused on 
blocking this receptor using antibodies such as cetuximab or panitumumab.39,56,63 On the 
other hand, platinum-drugs intercalate in the tumor DNA thereby inhibiting DNA 
replication and thus inducing cell death.8,9 Platinum containing drugs such as cisplatin, 
carboplatin or oxaliplatin, have a broad range of activity in malignant disease and are used 
to threat many types of cancer. In general, the antitumor effect of platinum drugs is the 
result of intercalation of platinum in the DNA helix, causing the formation of platinum-
DNA cross-links which ultimately leads to programmed cell death. 
Cisplatin was the first platinum drug approved for the treatment of both ovarian and 
testicular cancer in 1978.29 At present, more than 80% of patients with testicular cancer can 
be cured with cisplatin-based chemotherapy.31 It was also applied to threat other solid 
tumors such as cervical, head and neck, lung and bladder cancer. Unfortunately, neither of 
these cancer types could be treated with a similar efficiency as accounts for testicular 
cancer.64 Cisplatin was the most commonly used chemotherapy drug but its use is limited 
by severe side effects such as gastrointestinal and renal toxicities. For that reason, an 
analogue with less toxicity was developed that replaced cisplatin in many chemotherapeutic 
regiments. This second-generation platinum drug was carboplatin which has equivalent 
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activity, is more stable, and is less toxic than cisplatin. Especially neurotoxicity is less 
frequently observed when compared with cisplatin.26 Additionally, loss of hearing is less 
frequently observed in carboplatin-treated patients than is seen in patients treated with 
cisplatin.10,83 Carboplatin has a different spectrum of toxicity, as its primary toxic effects are 
heamatological.78 A third generation-platinum compound was oxaliplatin. Oxaliplatin 
shows no cross resistance with cisplatin and carboplatin which is an important benefit for 
the treatment of colorectal cancer. Colorectal cancer appeared extremely insensitive to 
cisplatin and carboplatin. Another advantage is the toxicity profile which is much less 
frequent, although neurotoxicity is still observed.26 
Cisplatin and carboplatin, that share the same mechanism of action, are fully cross resistant 
and form identical lesions in DNA. The mechanism of action of oxaliplatin is different and 
oxaliplatin does not share cross resistance.17,44 
4. Platinum induced DNA damage 
As mentioned above, the cytotoxic property of platinum (Pt)-drugs is the intercalation in 
cellular DNA, forming Pt-adducts, that consequently inhibit DNA replication and thus 
induce cell death.9 Although Pt-based drugs are the most widely used in cancer treatment, 
many tumors are completely resistant to these drugs. The difference in clinical response is 
thought to be due, in part, to the pharmacokinetics of these drugs, as summarized by 
Marsh et al.53 Once Pt is inside the cell, Pt-adducts are formed within the DNA and a 
cellular defense is activated (Figure 1). DNA is the preferential and cytotoxic target for 
platinating agents. Three different types of lesions can be formed: monoadducts, 
intrastrand crosslinks and interstrand crosslinks (Figure 2). Monoadducts are first formed, 
but almost all monoadducts then react to form crosslinks of which the majority is 
intrastrand crosslinks. Cisplatin- and carboplatin-induced crosslinks bend the DNA 
double helix by 32-35o toward the major groove, whereas oxaliplatin induced crosslinks 
bend the double helix even more.18  
Oxaliplatin adducts are bulkier and more hydrophobic than those formed by cisplatin and 
carboplatin, leading to different effects in the cell.55,65 Interstrand crosslinks induce more 
steric changes in DNA and are therefore considered to be more toxic. Cisplatin and 
oxaliplatin have been found to form the same types of adducts at the same sites on the 
DNA.35,58 Both cisplatin and oxaliplatin form approximately 60-65% intrastrand GG, 25-30% 
intrastrand AG, 5-10% intrastrand GNG, and 1-3% interstrand GG diadducts.20 
5. DNA repair mechanisms 
Platinum adducts are recognized by the cellular DNA repair system and resistance to 
platinum chemotherapy is achieved by activity of either the nucleotide excision repair 
(NER), mismatch repair (MMR) or homologous recombination (HR) pathways. On the other 
hand, mutations in key enzymes of these pathways result in sensitivity to platinum drugs. 
The nucleotide excision repair system deals with helix-distorting lesions that interfere with 
base pairing and obstruct transcription and normal replication. Therefore, NER is the most 
important pathway involved in the efficacy of platinum chemotherapeutic therapy.64 NER 
consists of two sub-pathways, global genome NER (GG-NER) that screens the entire 
genome for damage, and transcription coupled repair (TCR) that screens for lesions that 
might block elongating RNA polymerases.76 Specific protein complexes are involved in the  
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Fig. 1. Cellular response to platinum exposure. Figure taken from 
http://www.pharmgkb.org/do/serve?objId=PA150642262&objCls=Pathway. XPC, sensor 
for DNA damage, has not been depicted in this figure. 
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Fig. 2. Platinating agent adducts on DNA. Platinating agents are able to react with DNA to 
form monoadducts, intrastrand crosslinks, interstrand crosslinks and DNA–protein 
crosslinks. Figure taken from Rabik and Dolan.64 
first step of DNA damage recognition of GG-NER and TC-NER. Nomenclature of key 
enzymes involved in NER is listed in table 1. In GG-NER, XPC-hHR24B screens first on 
the basis of disrupted base pairing instead of lesions,75 explaining why mildly distorted 
damage is poorly repaired.75 In TCR, two specific enzymes are necessary to displace the 
stalled polymerase to make the lesion accessible for repair, CSA and CSB.46 Next steps in 
the NER system are identical (Figure 3). In general, the helix structure of about 30 base 
pairs around the damaged site, is opened by helicase XPD (part of the transcription factor 
TFIIH). Replication protein A binds to the undamaged site to stabilize the open DNA 
strands. Next, XPG and ERCC1/XPF cleave the DNA strand on both sides of the damaged 
site. The DNA replication machinery then completes the repair by filling the gap. In total, 
more than 25 proteins participate in NER and for almost all NER factors, mouse mutants 
have been generated14 some of which show features of premature ageing. In general, 
mutations in key enzymes of NER (such as XPD, XPB, XPG and ERCC1) compromise NER 
and cause developmental delay and affect transcription.80 The incidence of sun induced 
skin cancer is >1000 fold increased, whereas frequency of internal tumors is modestly 
elevated.  
The presence of dinucleotide repeats in the human genome is quite common and form 
unstable motifs in some cancers.36 This phenotype of microsatellite instability is caused by 
defects in MMR in the hereditary nonpolyposis colorectal cancer (HNPCC) and in a variety 
of sporadic cancers. Replication slippage of repetitive sequences introduce mispairing of 
nucleotides. These errors are removed by MMR and defects in MMR increase mutation rates 
leading to the development of tumors. The MMR system consists of four stages: 1) mismatch  
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Fig. 3. Two NER subpathways exist with partly distinct substrate specificity: global genome 
NER (GG-NER) surveys the entire genome for distorting injury, and transcription-coupled 
repair (TCR) focuses on damage that blocks elongating RNA polymerases. Figure taken 
from Hoeijmakers30 
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recognition, 2) recruitment of MMR factors, 3) identification and degradation of the 
mismatch containing strand, and 4) synthesis of the new strand (Figure 4). HNPCC is an 
inherited disease caused, in 60% of cases, by germline mutations in hMLH1 and hMSH2 
genes. Defects in hMSH6 cause late-onset HNPCC. Mice that are completely MMR deficient 
show a normal development28 but are cancer-prone. Homologous recombination (HR) has 
been proposed to play a role in repairing double-strand breaks as a result of cisplatin-
induced crosslinks.23 HR is not discussed in this chapter but different DNA repair systems 
are discussed in an excellent review by Hoeijmakers.30 
 
Gene name other name Function 
ERCC1 ERCC1 Forms complex with XPF for 5’-incision 
XPA XPA Verifies DNA damage 
XPB ERCC3 3’->5’ helicase 
XPC XPC Sensor for DNA damage 
XPD ERCC2 5’->3’ helicase 
XPE DDB2 Damage specific binding 
XPF ERCC4 Forms complex with ERCC1 for 5’-incision 
XPG ERCC5 3’-incision 
CSA ERCC8 Forms complex with CSB in TCR 
CSB ERCC6 Binds stalled polymerase II in TCR 
Table 1. Key enzymes in NER 
6. Cellular response to platinum-DNA adducts 
As described above, cells possess several DNA repair mechanisms for removing Pt-DNA 
adducts. The tumor specificity of oxaliplatin and cisplatin is not fully understood. Although 
both drugs cause DNA damage, the DNA repair mechanism of the host cell responds 
differently to these drugs. For example, damage caused by oxaliplatin is restored by the 
nucleotide excision repair mechanism, whereas the mismatch repair mechanism is also 
active to restore damage caused by cisplatin.10,54 So, what is the underlying mechanism that 
makes certain tumors more sensitive to cisplatin than to oxaliplatin? Resistance to platinum 
anticancer agents can result from decreased accumulation, increased inactivation by 
glutathione, or an increased ability of cells to tolerate Pt-DNA adducts.1 The ability of cells 
to repair platinum-induced DNA lesions is known to be an important factor in cisplatin 
cytotoxicity.13  
Interestingly, oxaliplatin induced DNA damage is as effectively repaired as cisplatin-
induced damage, as shown in plasmid reactivation experiments.71 The nucleotide excision 
repair has an extremely broad specificity, therefore it is not surprising that NER does not 
discriminate between oxaliplatin and cisplatin DNA adducts.66 The MMR system, however, 
is a crucial element in the repair of cisplatin-induced damage as this system does not appear  
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Fig. 4. Four principal steps in MMR can be delineated: (1) mismatch recognition; (2) 
recruitment of additional MMR factors; (3) search for a signal that identifies the wrong 
(newly synthesized) strand, followed by degradation past the mismatch; and (4) resynthesis 
of the excised tract. Figure taken from Hoeijmakers30 
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to recognize diaminocyclohexane-containing platinum64 DNA-adducts such as those caused 
by oxaliplatin. Although cells definitely respond differently to oxaliplatin and cisplatin, the 
mechanism behind that has still to be elucidated. Many studies that investigate the role of 
DNA repair mechanism in repairing DNA crosslinks, use cisplatin or mitomycin C as a 
model to induce such crosslinks.57 For instance the human ovarian cell line A2780 is 
sensitive to cisplatin but resistant to oxaliplatin.48 In this study it was shown that ERCC1 (a 
key enzyme in NER) mRNA is upregulated after exposure to cisplatin. Whether ERCC1 
mRNA levels are upregulated after exposure to oxaliplatin, is not known.  
7. The role of DNA repair enzymes in platinum resistance 
There is growing evidence that activity of DNA repair enzymes contributes to the 
interindividual differences in the anti-tumor effect of platinum drugs. Activity of DNA 
repair system is affected by functional SNPs in key enzymes, but also expression levels of 
such enzymes might differ between individuals. High levels of ERCC1 mRNA are 
associated with worse outcome in patients with bladder cancer treated with oxaliplatin.3 An 
SNP in exon 4 of ERCC1 (rs11615) was associated with better survival in non-small cell lung 
carcinoma treated with cisplatin,34 as was in colorectal cancer patients treated with 
oxaliplatin.62,81 The ERCC2 gene (XPD) is located at the same chromosome as ERCC1 and 
multiple non-synonomous SNPs in ERCC2 have been found associated with diminished 
DNA repair capacity.74 Since rs11615 is a silent SNP (not causing amino acid change) the 
association with diminished DNA repair capacity is suggested to be due to low ERCC1 
expression caused by a linked SNP (rs3212986) in its 3’NTR region.34 In vitro studies to test 
this hypothesis have not been performed. Interestingly, another gene in a reverse 
orientation, overlaps with ERCC1 3’NTR, and a role for this gene in DNA repair has been 
suggested.69 This gene was identified in 1999 as a CD3ε binding protein in T-cells and was 
therefore named CAST (CD3ε-associated signal transducer).86 Later, this gene was identified 
as a subunit of RNA Polymerase I.60 While the exact function of this Pol I-specific subunit is 
unknown, in mammalian cells the interaction with the activator of Pol I transcription, UBF, 
suggests a role for this subunit in facilitating the transition from transcription initiation to 
elongation at promoter escape.59 In another model it has been proposed that conformational 
changes in the Pol I enzyme complex through CAST convert the Pol I into a processive 
enzyme complex.60 Since the 3’ NTR of ERCC1 overlaps with CAST open reading frame, 
rs3212986 causes an amino acid change in CAST in a putative nuclear localization signal. It 
is likely that this SNP affects CAST function instead of ERCC1 expression. The hypothesis 
that CAST function is related with DNA repair is strengthened by its chromosomal location, 
between ERCC1 and ERCC2 (Figure 5).  
An effect of platinum-based drugs on RNA polymerase I transcription is not without 
precedent. Cisplatin-induced platinum adducts interact with proteins that contain high-
mobility-group (HMG) domains, such as UBF, an activator of Pol I transcription. UBF was 
able to bind cisplatin-modified DNA more avidly than unmodified DNA12 and caused a 
redistribution of UBF in the nucleolus and a block of rRNA synthesis in human cells.37 
Furthermore, UBF expression could increase the cell sensitivity to the chemotherapeutic 
reagent cis-diaminedichloroplatinum,32 perhaps by inhibiting repair of the DNA adducts. In 
addition, SNPs in CAST gene are associated with adult onset glioma11,85 and treatment 
outcome in multiple myeloma patients undergoing bone marrow transplantation.79 In view 
of the model where Pol I transcription of the rRNA genes is a sensor for DNA damage and 
www.intechopen.com
 
DNA Repair and Human Health 
 
606 
of the intricate association of CAST with Pol I, rs3212986 could result in a CAST-Pol I 
complex with a decreased capacity to elicit a DNA damage response. In those cells that carry 
this particular SNP, damage is therefore not efficiently repaired and this might result in 
increased cytotoxicity to platinum drugs, impairement of tumour growth and hence an 
increased patient survival. 
 
 
Fig. 5. Graphical presentation of the studied SNPs on chromosome 19. The ERCC1 
polymorphism is silent and does not result in an amino acid substitution. The CD3EAP 
polymorphism is G to A transversion in the 5  untranslated region of the mRNA. The 
PPP1R13L polymorphism is in intron 1 of the PPP1R13L gene. The ERCC2 D312N 
polymorphism gives rise to the Asp to Asn amino acid substitution in position 312 of 
ERCC2. ERCC2 K751Q gives rise to the Lys to Gln substitution in position 751 in ERCC2. 
Figure taken from Vangsted et al79 
8. Pharmacogenetic research of DNA repair genes in practice 
Cisplatin pharmacogenetics have been studied in esophageal cancer patients where several 
SNPs in NER were investigated. Two SNPs in ERCC1 and the SNP in ERCC1 3’-NTR (or CAST 
as discussed above) were found associated with improved overall survival.6 In testicular 
cancer cells, cisplatin sensitivity has been associated with low expression of ERCC1, however 
no SNPs were investigated in this study.77 Low expression of ERCC1 was also associated with 
oxaliplatin cytotoxicity in colorectal cancer cell lines when cetuximab (monoclonal antibody 
raised against EGFR) was co-administered.2 Platinum resistant ovarian cancer patients receive 
carboplatin together with gemcitabine49 that appeared to inhibit carboplatin induced 
interstrand crosslink repair.4,47 The role of ERCC1 in platinum treatment of non- small cell lung 
cancer with emphasis on carboplatin, has been reviewed by Vilmar and Sorensen.82 Recently, 
an explorative study has been performed to identify novel candidate genes related to 
oxaliplatin efficacy and toxicity in colorectal cancer patients, using a DNA repair array.43 Only 
ERCC5 (another factor in NER) and ATM (general responder to DNA damage) were found 
associated with clinical response. Discrepancies in association with SNPs in other DNA repair 
enzymes, present on the array, are discussed in this paper.  
9. Summary 
Since the entire human genome has been sequenced and 3,000,000 (1 in 1000 nucelotides) 
SNPs have been identified, more and more research is being performed to test effects of 
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specific SNPs. Pharmacogenetic research is particularly focused on SNPs with a high allele 
frequency and an altered response to drugs. Many association studies have been performed 
and SNPs in genes encoding for drug transport, uptake, metabolism, detoxification and 
DNA repair, are found to be related to drug response. SNPs in coding regions may alter 
gene function, however, associated SNPs are not causal per se but may be linked to another, 
yet unidentified, linked SNP. The ultimate goal of pharmacogenetic research is to predict an 
individuals’ response to drug therapy and subsequently adapt the therapeutic strategy. 
Peripheral blood can be taken to isolate chromosomal DNA and to genotype for specific 
SNPs, although tumor DNA might contain more mutations. In addition, expression levels of 
key enzymes may differ in tumor cells compared to normal cells. An approach to measure 
mRNA expression or to genotype tumor DNA could be the isolation of circulating tumor 
cells from peripheral blood. Whether this is feasible and cost effective for diagnostic 
healthcare should be investigated. In conclusion, more research is needed before any of the 
associated SNPs in DNA repair enzymes could be used to predict an individual response to 
a specific platinum-drug.  
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